Daniel J. Deangelo
Advanced in Acute Myelomonocytic Leukemia

Dr. Daniel J. Deangelo

Dana-Farber Cancer Institute, Inc.
Boston, MA
Advanced
in Acute Myelomonocytic Leukemia
Specialties:Hematology Oncology | Oncology | Hematology
Accepting New Patients
Offers Telehealth
OverviewInsuranceLocationsClinical Research

Overview

Daniel Deangelo is a Hematologist Oncology specialist and an Oncologist in Boston, Massachusetts. Dr. Deangelo and is rated as an Advanced provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Acute Myeloid Leukemia (AML), Systemic Mastocytosis, Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Deangelo is currently accepting new patients.

His clinical research consists of co-authoring 255 peer reviewed articles and participating in 22 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Albert Einstein College Of Medicine Of Yeshiva University
Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in MA
Hospital Affiliations
Massachusetts General Hospital
Brigham And Women's Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Locations

DANA-FARBER CANCER INSTITUTE, INC.
450 Brookline Ave, Boston, MA 02215

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Drug, Procedure, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: February 24, 2025
Intervention Type: Drug
Study Drugs: Azacitidine, IMGN632, Venetoclax
Study Phase: Phase 1/Phase 2
A Phase 1b Trial of Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Patients With Hematological Malignancies
A Phase 1b Trial of Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Patients With Hematological Malignancies
Enrollment Status: Terminated
Publish Date: January 17, 2025
Intervention Type: Drug
Study Drugs: Magrolimab, Azacitidine
Study Phase: Phase 1
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL
Enrollment Status: Suspended
Publish Date: January 15, 2025
Intervention Type: Biological, Drug, Procedure, Other
Study Drugs: Allopurinol, Cytarabine, Daunorubicin Hydrochloride, Vincristine Sulfate, Dexamethasone, Pegylated L-Asparaginase, Methotrexate, Cyclophosphamide, Mercaptopurine, Rituximab, Doxorubicin, Thioguanine, Inotuzumab
Study Phase: Phase 3
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2024
Intervention Type: Procedure, Drug
Study Drugs: Cytarabine, Daunorubicin, Uproleselan
Study Phase: Phase 2/Phase 3
A Phase 1/2, Multi-center, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients With CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies
A Phase 1/2, Multi-center, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients With CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: December 16, 2024
Intervention Type: Drug
Study Drug: IMGN-632 CD123-Targeting Antibody-Drug Conjugate
Study Phase: Phase 1/Phase 2
A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia
A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: December 10, 2024
Intervention Type: Procedure, Drug
Study Drug: Ibrutinib
Study Phase: Phase 2
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2024
Intervention Type: Drug
Study Drug: Avapritinib
Study Phase: Phase 2
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2024
Intervention Type: Drug
Study Drug: Avapritinib
Study Phase: Phase 2
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Enrollment Status: Terminated
Publish Date: July 29, 2024
Intervention Type: Drug
Study Drug: Uproleselan
Study Phase: Phase 3
A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)
A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Enrollment Status: Completed
Publish Date: March 18, 2024
Intervention Type: Drug
Study Drugs: ABL-001, Dasatinib, Nilotinib, Imatinib
Study Phase: Phase 1
A Phase 1 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
A Phase 1 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
Enrollment Status: Completed
Publish Date: March 17, 2023
Intervention Type: Drug
Study Drug: Avapritinib
Study Phase: Phase 1
A Phase I, Open Label, Multicenter, Dose-escalation Study of HDM201 in Adult Patients With Advanced Solid and Hematological Tumors Characterized by Wild-type TP53
A Phase I, Open Label, Multicenter, Dose-escalation Study of HDM201 in Adult Patients With Advanced Solid and Hematological Tumors Characterized by Wild-type TP53
Enrollment Status: Completed
Publish Date: May 21, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Multinational Study of MCLA-117 in Acute Myelogenous Leukemia
A Phase 1, Multinational Study of MCLA-117 in Acute Myelogenous Leukemia
Enrollment Status: Unknown
Publish Date: May 10, 2021
Intervention Type: Drug
Study Drug: MCLA-117
Study Phase: Phase 1
A Phase II Study of the Aurora A Kinase Inhibitor Alisertib in Combination With 7+3 Induction Chemotherapy in Patients With High-risk Acute Myeloid Leukemia
A Phase II Study of the Aurora A Kinase Inhibitor Alisertib in Combination With 7+3 Induction Chemotherapy in Patients With High-risk Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: May 05, 2020
Intervention Type: Drug
Study Phase: Phase 2
Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults
Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults
Enrollment Status: Completed
Publish Date: November 26, 2019
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b/Randomized Phase 2 Study to Evaluate LY3039478 in Combination With Dexamethasone in T-ALL/T-LBL Patients
A Phase 1b/Randomized Phase 2 Study to Evaluate LY3039478 in Combination With Dexamethasone in T-ALL/T-LBL Patients
Enrollment Status: Completed
Publish Date: September 11, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1, Multi-center, Open-label Study of IMGN779 Administered Intravenously in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia
A Phase 1, Multi-center, Open-label Study of IMGN779 Administered Intravenously in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: September 04, 2019
Intervention Type: Drug
Study Phase: Phase 1
A Phase I/II, Open-label Multicenter Trial to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia
A Phase I/II, Open-label Multicenter Trial to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: May 17, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 18 Less Clinical Trials

259 Total Publications

Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia.
Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia.
Journal: The New England journal of medicine
Published: November 27, 2024
Similar Doctors
Expertise in
7
conditions
Dr. Douglas V. Faller
Hematology
Expertise in
7
conditions
Dr. Douglas V. Faller
Hematology
830 Harrison Ave, Moakley, 3rd Floor, 
Boston, MA 
 (1.7 mi)
617-638-6428
Languages Spoken:
English

Douglas Faller is a Hematologist in Boston, Massachusetts. Dr. Faller and is rated as a Distinguished provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Acute Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome (MDS), and Acute Myeloid Leukemia (AML).

Expertise in
5
conditions
Dr. Robert J. Fram
Hematology Oncology
Expertise in
5
conditions
Dr. Robert J. Fram
Hematology Oncology
Immunogen, Inc., 128 Sidney St, 
Cambridge, MA 
 (3.2 mi)
617-995-4909
Languages Spoken:
English

Robert Fram is a Hematologist Oncology provider in Cambridge, Massachusetts. Dr. Fram and is rated as a Distinguished provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Acute Myelomonocytic Leukemia, Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML).

Expertise in
35
conditions
Dr. Malgorzata Mcmasters
Hematology Oncology | Hematology | Oncology
Expertise in
35
conditions
Dr. Malgorzata Mcmasters
Hematology Oncology | Hematology | Oncology

Harvard Medical Faculty Phys At Beth Israel Deaconess Med Ctr Inc

330 Brookline Ave, 
Boston, MA 
 (0.2 mi)
617-754-8612
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Malgorzata Mcmasters is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Mcmasters and is rated as a Distinguished provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. Her top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myelomonocytic Leukemia, Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Mcmasters is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile